Chemoembolization (TACE) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transarterial chemoembolization (TACE) is a minimally invasive, image-guided interventional radiology procedure that delivers a concentrated dose of chemotherapy directly to a tumour while simultaneously blocking its arterial blood supply. The technique exploits the unique vascular biology of hepatic tumours: primary liver cancers (hepatocellular carcinoma, HCC) and many liver metastases derive nearly all their blood supply from the hepatic artery, while the normal liver parenchyma receives approximately 75% of its blood from the portal vein. This differential allows selective catheterisation of tumour-feeding hepatic arteries and delivery of a chemotherapy-embolisation mixture that achieves intratumoral drug concentrations up to 100 times higher than systemic intravenous chemotherapy, with minimal systemic toxicity.

Hepatocellular carcinoma is the sixth most common cancer globally and the third leading cause of cancer-related mortality, with approximately 906,000 new cases diagnosed annually (Global Cancer Statistics 2020). A significant proportion of patients — estimated at 30–50% at diagnosis — present with intermediate-stage multifocal disease (Barcelona Clinic Liver Cancer stage B, BCLC-B), which is beyond surgical cure but without vascular invasion or extrahepatic spread. TACE is the established standard of care for this patient population and the only locoregional therapy demonstrated in two landmark randomised controlled trials (Llovet et al., 2002; Lo et al., 2002) to confer a significant overall survival benefit compared to conservative management (median survival 19–20 months vs. 10–16 months with best supportive care).

Two main technical variants are used in contemporary practice. Conventional TACE (cTACE) mixes a chemotherapy agent (doxorubicin, cisplatin, or mitomycin-C) with Lipiodol (ethiodised oil) to form an oily emulsion, followed by embolic particles to occlude the feeding artery. Drug-eluting bead TACE (DEB-TACE) uses microsphere beads (LC Bead, DC Bead) that are pre-loaded with doxorubicin and release the drug in a sustained, controlled fashion over days after implantation. DEB-TACE produces lower systemic doxorubicin exposure and more predictable embolisation, though randomised trials (PRECISION V) have not demonstrated a statistically significant survival advantage over cTACE in unselected populations. The choice between modalities depends on tumour characteristics, liver function, institutional expertise, and emerging evidence supporting individualised approaches.

TACE is employed across a range of primary hepatic and secondary (metastatic) tumour types with differential evidence bases:

• Hepatocellular carcinoma (HCC) — intermediate stage (BCLC-B): The primary and best-evidenced indication. Multifocal HCC without macrovascular invasion or extrahepatic spread, in patients with preserved liver function (Child-Pugh A or selected Child-Pugh B7). First-line locoregional therapy per EASL, AASLD, and BCLC guidelines.
• HCC as bridging therapy: Used in patients awaiting liver transplantation to prevent tumour progression beyond Milan criteria (single lesion ≤5 cm or up to 3 lesions ≤3 cm), achieving pathological complete response in approximately 25% of explanted livers.
• HCC as downstaging therapy: Applied to reduce tumour burden in patients initially outside transplant criteria (T3) to within acceptable limits, enabling transplant eligibility.
• Colorectal cancer liver metastases (CRCLM): TACE with irinotecan-loaded beads (DEBIRI-TACE) is used in chemotherapy-refractory patients, demonstrating survival benefit in randomised trials (DEBIRI trial: 22 months vs. 15 months, median OS).
• Neuroendocrine tumour (NET) liver metastases: Hepatic chemoembolization is highly effective in controlling symptoms (carcinoid syndrome, hormone hypersecretion) and achieving radiological response in 50–85% of patients with well-differentiated liver-dominant NETs.
• Hepatic metastases from other primaries: Ocular melanoma, cholangiocarcinoma, and selected breast cancer liver metastases may be treated with TACE in carefully selected cases where systemic options have been exhausted or where liver-dominant disease is present.
• Intrahepatic cholangiocarcinoma (iCCA): Emerging evidence supports DEB-TACE as salvage therapy for unresectable iCCA, though data are less robust than for HCC.

Optimal candidates for TACE meet the following criteria:

• HCC of intermediate stage (BCLC-B) or selected early stage when RFA/surgery is not feasible
• Preserved hepatic reserve: Child-Pugh class A or well-selected B7 (score ≤7) with total bilirubin <2 mg/dL, absence of clinically significant ascites, and no encephalopathy
• ECOG performance status 0–1 (ambulatory, fully active or restricted in physically strenuous activity)
• Absence of main portal vein thrombosis (complete occlusion of the main portal trunk is a contraindication due to risk of hepatic decompensation; segmental branch occlusion may be acceptable)
• No extrahepatic metastases (or limited volume controlled extrahepatic disease in selected cases)
• Adequate renal function (creatinine <1.5 × ULN) and no clinically significant coagulopathy
• Absence of contrast allergy (or manageable with premedication) — iodinated contrast is used for fluoroscopic guidance

Contraindications (absolute or relative) include:

• Decompensated cirrhosis (Child-Pugh C) — excessive risk of post-embolisation hepatic failure
• Main portal vein thrombosis with absent hepatopetal portal flow
• Hepatic encephalopathy (any grade) at baseline
• Severe biliary obstruction or bilioenteric anastomosis (risk of biloma and infection from compromised biliary drainage)
• Uncorrectable coagulopathy (INR >2.0 not correctable with fresh frozen plasma or vitamin K)
• Platelet count <50,000/μL (thrombocytopenia from portal hypertension is common in cirrhosis; transfusion threshold varies by protocol)
• Active systemic infection or sepsis
• Severe cardiac or pulmonary disease precluding conscious sedation or general anaesthesia
• Uncorrectable arteriovenous shunting to the lung or gastrointestinal tract (risk of non-target embolization)

Several TACE modalities and related locoregional therapies are available, often used sequentially or in combination:

• Conventional TACE (cTACE) with Lipiodol: Under fluoroscopic guidance, a catheter is advanced through the femoral or radial artery and selectively placed into the hepatic artery supplying the tumour. An emulsion of doxorubicin (50–75 mg/m²) or cisplatin mixed with Lipiodol is injected, followed by gelatin sponge particles or polyvinyl alcohol (PVA) microspheres to achieve arterial occlusion. Lipiodol acts as a drug-delivery vehicle and provides post-procedural CT visibility (Lipiodol retention in tumour on follow-up CT correlates with necrosis). Most widely practiced technique globally due to low equipment cost and extensive operator familiarity.
• Drug-Eluting Bead TACE (DEB-TACE): Microspheres (100–300 μm or 300–500 μm diameter) pre-loaded with doxorubicin (DC Bead, LC Bead LUMI) are injected to produce simultaneous embolisation and sustained local drug release over 3–7 days. Reduces systemic doxorubicin Cmax by approximately 50% versus cTACE, reducing alopecia, mucositis, and systemic toxicity. European Society of Interventional Radiology (CIRSE) technical recommendations support DEB-TACE for patients with significant cardiovascular or hepatic fragility where systemic drug exposure must be minimised.
• Selective/Super-selective TACE: Using microcatheter technology, the catheter tip is advanced into subsegmental or even sub-subsegmental feeding arteries. This precision approach maximises intratumoral drug delivery while minimising normal parenchymal ischaemia, enabling treatment in patients with more compromised liver function than tolerable with lobar TACE. Associated with improved disease control and reduced non-target embolization rates.
• Radioembolization (SIRT — Selective Internal Radiation Therapy): A closely related but distinct procedure. Yttrium-90 (Y-90) microspheres (SIR-Spheres, TheraSphere) are administered via the hepatic artery to deliver internal radiation to tumours. Response rates for HCC are comparable to TACE, with higher tolerability in Child-Pugh B patients. Preferred in patients where conventional embolization is not feasible due to portal vein compromise.
• TACE combined with systemic therapy: The LAUNCH trial (2022) and IMbrave050 data support combination of TACE with systemic agents (sorafenib, lenvatinib, atezolizumab-bevacizumab) to target both local disease and micrometastatic spread, with emerging evidence of improved progression-free survival in intermediate-stage HCC.

TACE offers meaningful clinical benefit as a locoregional therapy for unresectable hepatic malignancies:

• Overall survival benefit: The two pivotal RCTs establishing TACE as standard of care (Llovet et al., Lancet 2002; Lo et al., Hepatology 2002) demonstrated 2-year survival rates of 27–31% with TACE versus 11–17% with best supportive care in intermediate-stage HCC. A meta-analysis of 7 randomised trials confirmed a significant survival benefit (HR 0.53; 95% CI 0.37–0.76).
• Tumour response: Per modified RECIST (mRECIST) criteria, objective response rates (complete + partial response) are 50–60% for cTACE and 40–70% for DEB-TACE. Complete necrosis on follow-up imaging occurs in 15–55% of lesions depending on size (<3 cm lesions achieve higher complete response rates).
• Bridging to transplant: TACE achieves successful bridging (tumour within Milan criteria at time of transplantation) in 50–80% of eligible patients, with post-transplant 5-year survival rates equivalent to those who were within criteria at listing.
• Symptom and hormone control in NETs: TACE achieves biochemical response (reduction in 5-HIAA, chromogranin A) in 60–80% of patients with carcinoid syndrome from hepatic NET metastases, providing clinically significant symptom relief for a median of 12–15 months.
• Minimally invasive outpatient-feasible delivery: TACE is performed via a small groin or wrist catheter puncture without open surgery, typically requiring only 1–2 overnight hospital stays, with patients returning to normal activity within 1–2 weeks.

TACE carries a defined risk profile that is managed through careful patient selection, technical precision, and post-procedural monitoring:

• Post-embolization syndrome (PES): The most common expected effect rather than complication, occurring in 60–80% of patients. Characterised by fever (low-grade, 38–38.5°C), right upper quadrant pain, nausea, vomiting, and fatigue arising from hepatic ischaemia and tumour necrosis. Typically resolves within 3–5 days with supportive care (analgesics, antiemetics, hydration). Severe PES requiring extended hospitalisation occurs in approximately 5%.
• Hepatic decompensation: Transient elevation of liver enzymes (AST, ALT, ALP) occurs in virtually all patients; acute-on-chronic liver failure with worsening Child-Pugh score occurs in 5–10% of patients with pre-existing cirrhosis. Risk is highest with lobar TACE in Child-Pugh B patients and bilobar simultaneous treatment.
• Non-target embolization: Inadvertent embolisation of non-tumour hepatic parenchyma, gallbladder (chemocholecystitis in 1–3%), stomach, or intestine can produce ischaemic injury. Minimised by super-selective catheterisation and pre-procedural cone-beam CT imaging to map feeding vessels.
• Bile duct injury / biloma: Ischaemic injury to biliary radicles occurs in <1% of cases but is more common in patients with prior bilioenteric anastomosis or bile duct dilatation. May require percutaneous drainage.
• Hepatic abscess: Bacterial infection within an area of tumour necrosis, occurring in approximately 1–2%; risk elevated in patients with prior bilioenteric anastomosis or biliary stents. Requires prolonged antibiotic therapy and sometimes percutaneous drainage.
• Access site complications: Haematoma, pseudoaneurysm, or arteriovenous fistula at the femoral or radial arterial puncture site (<1% with modern closure devices and radial access).
• Renal impairment: Contrast-induced nephropathy from iodinated contrast; minimised by adequate pre-procedural hydration and dose limitation in patients with pre-existing renal insufficiency.

Immediate post-procedural period (0–48 hours): Patients are observed for 4–6 hours in a recovery unit or are admitted overnight. Vital signs, liver function, and access site are monitored. Post-embolization syndrome symptoms (pain, fever, nausea) are managed proactively with analgesics (morphine PCA or oral opioids), ondansetron, and paracetamol. Intravenous hydration reduces contrast nephropathy risk. Patients are typically discharged 24–48 hours post-procedure if haemodynamically stable and pain controlled.

Short-term recovery (Weeks 1–2): Fatigue and mild right upper quadrant discomfort are expected for 1–2 weeks. Patients are advised to rest, maintain oral hydration, and avoid strenuous activity. LFTs are checked at 1 week to assess hepatic response and identify decompensation. Fever persisting beyond 5 days or worsening pain should prompt evaluation for hepatic abscess.

Tumour response assessment (4–8 weeks): Contrast-enhanced MRI or CT is performed at 4–6 weeks using mRECIST criteria to evaluate treatment response. Complete response (no viable tumour enhancement) indicates successful treatment. Partial response or stable disease typically prompts planning of a second TACE session. Progressive disease (viable tumour growth despite treatment) triggers consideration of alternative therapies (sorafenib, lenvatinib, Y-90 radioembolization, immunotherapy).

Long-term monitoring: Patients treated with TACE as part of transplant bridging are listed on the transplant waiting list and undergo repeat TACE every 3–6 months as needed to maintain tumour within criteria. Non-transplant candidates receive TACE on demand (repeat sessions when new viable tumour is identified on surveillance imaging) — the EASL on-demand strategy has demonstrated superior outcomes compared to scheduled repeat TACE. AFP (alpha-fetoprotein) and liver function tests are monitored at each visit. Combination with sorafenib or other systemic agents is considered when tumour control deteriorates.

TACE costs vary substantially by country, technical approach, number of sessions, and whether cTACE or DEB-TACE is performed. Per-session representative costs:

• United States: USD 15,000–35,000 per session (hospital facility, catheter lab, interventional radiologist, anaesthesia, imaging, and consumables)
• United Kingdom (NHS): Covered for eligible patients at QIPP-approved hepatobiliary centres; private: GBP 8,000–18,000 per session
• Germany: EUR 10,000–20,000 per session (statutory insurance covers HCC TACE in approved centres)
• India (tertiary centres): USD 2,500–6,000 per session (JCI/NABH-accredited oncology hospitals in Mumbai, Chennai, Hyderabad)
• Thailand: USD 4,000–9,000 per session
• Turkey: USD 3,500–8,000 per session
• Singapore: USD 8,000–15,000 per session

Cost determinants:

• DEB-TACE microspheres add USD 1,500–4,000 per session versus conventional cTACE with Lipiodol
• Number of lesions and lobes treated (bilobar disease may require staged sessions)
• Imaging costs (pre-procedural MRI/CT, intraoperative cone-beam CT, post-procedural response imaging)
• Ancillary treatments (antiemetics, analgesics, prophylactic antibiotics, hospitalisation)
• Combination systemic therapy costs (sorafenib, lenvatinib: USD 5,000–10,000/month in the USA)
• Most countries with universal healthcare systems cover TACE for HCC when performed at approved oncology centres; reimbursement status should be confirmed before international travel

TACE exists within a broader ecosystem of hepatic locoregional and systemic therapies; the optimal strategy is determined by tumour stage, liver function, and treatment history:

• Curative surgical resection: The preferred treatment for solitary HCC in patients with adequate hepatic reserve (preserved liver function, no portal hypertension). Achieves 5-year survival of 60–80% for early-stage HCC but is applicable to only 20–30% of patients at diagnosis due to advanced disease or co-existing cirrhosis.
• Liver transplantation: The only potentially curative option that simultaneously treats HCC and the underlying cirrhosis. Achieves 5-year survival >70% for patients within Milan criteria. TACE serves as a bridging therapy during transplant wait time.
• Radiofrequency ablation (RFA) / microwave ablation (MWA): Percutaneous thermal ablation is curative for HCC lesions ≤3 cm and preferred over TACE for single small tumours in patients unsuitable for surgery. Produces complete response in 80–95% of lesions ≤2 cm. For lesions 3–5 cm, RFA combined with TACE is superior to either alone.
• Stereotactic body radiotherapy (SBRT): High-dose precision radiotherapy (typically 3–5 fractions) achieves local control rates of 80–90% for HCC lesions ≤5 cm. Effective when vascular anatomy precludes safe catheter access for TACE or when prior TACE has failed.
• Selective internal radiation therapy (SIRT / Y-90 radioembolization): Hepatic artery delivery of Yttrium-90 microspheres providing internal brachytherapy. Achieves comparable response rates to TACE with potentially superior tolerability in portal vein thrombosis. The SIRVENIB and SARAH trials showed non-inferiority to sorafenib in advanced-stage HCC.
• Systemic targeted therapy and immunotherapy: Sorafenib (SHARP trial) and lenvatinib (REFLECT trial) are first-line systemic agents for advanced-stage HCC (BCLC-C). Atezolizumab plus bevacizumab (IMbrave150 trial) has become first-line preferred therapy for eligible patients with preserved liver function and performance status, demonstrating superior OS and PFS over sorafenib.
• Irreversible electroporation (IRE / NanoKnife): Non-thermal ablation using electrical pulses to induce cell death without heat, enabling treatment of perihilar tumours adjacent to major bile ducts and vessels that preclude thermal ablation.